Insulet Corporation filings document the financial, regulatory, governance, and operating disclosures of a medical device company built around the Omnipod tubeless insulin delivery platform. Current reports record quarterly and annual results, Omnipod revenue categories, U.S. and international performance, drug delivery revenue, and related financial-condition disclosures.
Insulet’s SEC filings also cover Regulation FD updates on product-quality and medical device correction matters, material supply agreements, stock repurchase authorizations, executive severance arrangements, auditor changes, and proxy governance. Its definitive proxy materials describe board oversight, executive compensation, leadership structure, and other shareholder-voting matters tied to the company’s public-company governance.
INSULET CORP director Robert Luther Huffines received an award of 111 deferred common stock units of Insulet common stock on March 31, 2026, valued at $209.84 per unit. This grant was made in lieu of cash board compensation under the company’s Deferred Compensation Plan for Non-Employee Directors and increased his reported holdings to 638 shares or units.
The deferred common stock units will convert into the same number of Insulet common shares upon distribution, with any fractional share value paid in cash. Distribution occurs at the director’s election, either in a lump sum or in substantially equal annual installments, consistent with the plan’s terms.
The Vanguard Group filed Amendment No. 14 to Schedule 13G/A reporting that it beneficially owns 0 shares of Insulet Corp Common Stock, representing 0% of the class as disclosed in the amendment.
The amendment explains an internal realignment effective January 12, 2026, under SEC Release No. 34-39538 that resulted in certain subsidiaries and business divisions of The Vanguard Group reporting ownership separately. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 03/27/2026.
Insulet Corporation announced a voluntary medical device correction for specific lots of its Omnipod® 5 Pods in the U.S. after identifying a manufacturing issue that can cause small tears in internal tubing and under-delivery of insulin.
The company has received 18 reports of serious adverse events tied to high blood glucose and diabetic ketoacidosis, but no deaths, and has notified the FDA. The affected lots represent about 1.5% of annual Omnipod 5 pod production, and Insulet does not expect shipment or new-patient-start disruptions. Customers can check lot numbers online and obtain free replacement Pods.
Insulet currently expects to incur up to $40 million of related costs in 2026, which will be excluded from adjusted results, and it is not changing previously issued 2026 guidance.
Insulet Corporation reported entering into a severance agreement and release with former Chief Financial Officer Ana M. Chadwick. The agreement implements severance and other post-termination benefits that were already disclosed under prior arrangements and the company’s Amended and Restated Executive Severance Plan.
The filing explains that the Severance Agreement does not add or change any material compensation or benefits terms. It includes standard provisions such as a release of legal claims, mutual non-disparagement, and requirements that Ms. Chadwick comply with existing executive severance and confidentiality, non-solicit, non-compete, and intellectual property assignment agreements.
INSULET CORP senior vice president Prem Singh reported routine share dispositions related to tax withholding on vested equity. On February 27, 2026, a total of 269 shares of common stock were withheld at $246.61 per share to cover tax obligations from restricted stock units vesting. These transactions are coded as tax-withholding dispositions, not open-market sales, and Singh continued to hold several thousand shares directly afterward.
INSULET CORP senior vice president Laetitia Cousin reported small share disposals tied to tax withholding, not open-market selling. On the vesting of restricted stock units, 200 and 53 shares of common stock were withheld at a price of $246.61 per share to cover associated tax obligations. After these transactions, she directly held 5,674 shares of Insulet common stock.
INSULET CORP executive reports tax-related share withholdings
Insulet Corp Group VP, CAO and Controller Lauren Budden reported two Form 4 transactions on common stock dated February 27, 2026. The transactions were coded "F," meaning shares were withheld to satisfy tax obligations upon vesting of restricted stock units, rather than open-market sales.
Budden had 119 shares and 99 shares withheld at a reference price of $246.61 per share to cover associated taxes. Following these non-market dispositions, she directly holds 8,526 shares of Insulet common stock.
Insulet Corp SVP and General Counsel John W. Kapples reported routine share withholding to cover taxes on vested stock awards. On February 27, 2026, 411 and 194 shares of Insulet common stock were disposed of at $246.61 per share through tax-withholding transactions.
According to the filing, these dispositions were for tax obligations tied to restricted stock units vesting, rather than open-market sales. After these transactions, Kapples directly held 27,514 shares of Insulet common stock.
INSULET CORP EVP and COO Eric Benjamin reported tax-related share dispositions, not open-market sales. On February 27, 2026, he surrendered 644 and 268 shares of common stock at $246.61 per share to cover tax obligations upon vesting of restricted stock units, and continued to hold directly owned shares afterward.
INSULET CORP senior executive Prem Singh reported routine equity compensation activity. He received a grant of 2,140 shares of common stock as a restricted stock unit award that vests over three years and 5,570 non-qualified stock options that vest over four years. On a separate date, 138 shares of common stock were withheld to satisfy tax obligations upon RSU vesting, a non-market transaction, leaving him with 7,160 directly owned shares.